Серповидно-клеточная анемия

Список литературы

Основные статьи

National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: expert panel report, 2014. Sep 2014 [internet publication].Полный текст

Wang WC, Ware RE, Miller ST, et al; BABY HUG investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011 May 14;377(9778):1663-72.Полный текст  Аннотация

Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010 Jun;85(6):403-8.Полный текст  Аннотация

Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017 Feb 2;376(5):429-39.Полный текст  Аннотация

Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019 Aug 8;381(6):509-19.Полный текст  Аннотация

Howard J, Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet. 2013 Mar 16;381(9870):930-8. Аннотация

Mantadakis E, Cavender JD, Rogers ZR, et al. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):518-22. Аннотация

Статьи, указанные как источники

1. Pass KA, Lane PA, Fernhoff PM, et al. US newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN). J Pediatr. 2000 Oct;137(suppl 4):S1-46. Аннотация

2. National Health Service (UK). NHS sickle cell and thalassaemia (SCT) screening programme. 2018 [internet publication].Полный текст

3. Dunston T, Rowland R, Huntsman RG, et al. Sickle-cell haemoglobin C disease and sickle-cell beta thalassaemia in white South Africans. S Afr Med J. 1972 Sep 30;46(39):1423-6. Аннотация

4. Lorey FW, Arnopp J, Cunningham GC. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genet Epidemiol. 1996;13(5):501-12. Аннотация

5. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010 Apr;38(suppl 4):S512-21. Аннотация

6. Ohene-Frempong K, Nkrumah FK. Sickle cell disease in Africa. In: Embry SH, Hebbel RP, Mohandas N, et al, eds. Sickle cell disease: basic principles and clinical practice. New York, NY: Raven Press Ltd; 1994.

7. Allison A. Abnormal haemoglobin and erythrocyte enzyme-deficiency traits. In: Harrison G, ed. Genetical variations in human populations. New York, NY; 1961.

8. Wethers DL. Sickle cell disease in childhood: part I. Laboratory diagnosis, pathophysiology and health maintenance. Am Fam Physician. 2000 Sep 1;62(5):1013-20, 1027-8.Полный текст  Аннотация

9. Hebbel RP, Yamada O, Moldow CF, et al. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest. 1980 Jan;65(1):154-60.Полный текст  Аннотация

10. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004 Mar;11(2):129-51. Аннотация

11. Yale SH, Nagib N, Guthrie T. Approach to the vaso-occlusive crisis in adults with sickle cell disease. Am Fam Physician. 2000 Mar 1;61(5):1349-56, 1363-4. Аннотация

12. Kato GJ, Onyekwere OC, Gladwin MT. Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr Hematol Oncol. 2007 Apr-May;24(3):159-70.Полный текст  Аннотация

13. Dormandy E, Gulliford M, Bryan S, et al. Effectiveness of earlier antenatal screening for sickle cell disease and thalassaemia in primary care: cluster randomised trial. 2010 Oct 5;341:c5132. Полный текст  Аннотация

14. US Preventive Services Task Force. Sickle cell disease (hemoglobinopathies) in newborns: screening - referred topic. Sep 2007 [internet publication].Полный текст

15. Gill FM, Sleeper LA, Weiner SJ, et al; Cooperative Study of Sickle Cell Disease. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood. 1995 Jul 15;86(2):776-83.Полный текст  Аннотация

16. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000 Jan 13;342(2):83-9.Полный текст  Аннотация

17. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999 Apr 1;340(13):1021-30. Аннотация

18. Vosmaer A, Pereira RR, Koenderman JS, et al. Coagulation abnormalities in Legg-Calvé-Perthes disease. J Bone Joint Surg Am. 2010 Jan;92(1):121-8. Аннотация

19. Public Health England. Newborn blood spot screening: programme overview. Nov 2018 [internet publication].Полный текст

20. Eckman J. Neonatal screening. In: Embry SH, Hebbel RP, Mohandas N, et al, eds. Sickle cell disease: basic principles and clinical practice. New York, NY: Raven Press Ltd.; 1994.

21. Cherry MG, Greenhalgh J, Osipenko L, et al. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. Health Technol Assess. 2012;16(43):1-129.Полный текст  Аннотация

22. Alexandrov AV, Sloan MA, Tegeler CH, et al; American Society of Neuroimaging Practice Guidelines Committee. Practice standards for transcranial Doppler (TCD) ultrasound. Part II. Clinical indications and expected outcomes. J Neuroimaging. 2012 Jul;22(3):215-24. Аннотация

23. Asnani MR, Quimby KR, Bennett NR, et al. Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications. Cochrane Database Syst Rev. 2016 Oct 6;(10):CD011175.Полный текст  Аннотация

24. National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: expert panel report, 2014. Sep 2014 [internet publication].Полный текст

25. Rankine-Mullings AE, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev. 2017 Oct 10;(10):CD003427.Полный текст  Аннотация

26. Brawley OW, Cornelius LJ, Edwards LR, et al. NIH consensus development statement on hydroxyurea treatment for sickle cell disease. NIH Consens State Sci Statements. 2008 Feb 27-29;25(1):1-30. Аннотация

27. Dekker LH, Fijnvandraat K, Brabin BJ, et al. Micronutrients and sickle cell disease, effects on growth, infection and vaso-occlusive crisis: a systematic review. Pediatr Blood Cancer. 2012 Aug;59(2):211-5. Аннотация

28. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease - life expectancy and risk factors for early death. N Engl J Med. 1994 Jun 9;330(23):1639-44.Полный текст  Аннотация

29. Redwood AM, Williams EM, Desai P, et al. Climate and painful crisis of sickle-cell disease in Jamaica. BMJ. 1976 Jan 10;1(6001):66-8.Полный текст  Аннотация

30. Mohan J, Marshall JM, Reid HL, et al. Peripheral vascular response to mild indirect cooling in patients with homozygous sickle cell (SS) disease and the frequency of painful crisis. Clin Sci (Lond). 1998 Feb;94(2):111-20. Аннотация

31. Beutler E. Disorders of hemoglobin structure: sickle cell anemia and related abnormalities. In: Lichtman MA, Beutler E, Kaushansky K, et al, eds. Williams hematology. 7th ed. New York, NY: McGraw-Hill; 2006:667-700.

32. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995 May 18;332(20):1317-22.Полный текст  Аннотация

33. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008 Jun 17;148(12):939-55.Полный текст  Аннотация

34. Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess (Full Rep). 2008 Mar;(165):1-95. Аннотация

35. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005 Oct 1;106(7):2269-75.Полный текст  Аннотация

36. Scott JP, Hillery CA, Brown ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr. 1996 Jun;128(6):820-8. Аннотация

37. Wang WC, Helms RW, Lynn HS, et al. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr. 2002 Feb;140(2):225-9. Аннотация

38. Wang WC, Ware RE, Miller ST, et al; BABY HUG investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011 May 14;377(9778):1663-72.Полный текст  Аннотация

39. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004 Mar 15;103(6):2039-45.Полный текст  Аннотация

40. Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2017 Apr 20;(4):CD002202.Полный текст  Аннотация

41. Ware RE, Helms RW; SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012 Apr 26;119(17):3925-32.Полный текст  Аннотация

42. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999 Sep 1;94(5):1550-4.Полный текст  Аннотация

43. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003 Apr 2;289(13):1645-51.Полный текст  Аннотация

44. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010 Mar 25;115(12):2354-63.Полный текст  Аннотация

45. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010 Jun;85(6):403-8.Полный текст  Аннотация

46. Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of L-glutamine in sickle cell disease. N Engl J Med. 2018 Jul 19;379(3):226-35. Аннотация

47. Quinn CT. L-glutamine for sickle cell anemia: more questions than answers. Blood. 2018 Aug 16;132(7):689-93. Аннотация

48. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017 Feb 2;376(5):429-39.Полный текст  Аннотация

49. Kutlar A, Kanter J, Liles DK, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. Am J Hematol. 2019 Jan;94(1):55-61.Полный текст  Аннотация

50. Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019 Aug 8;381(6):509-19.Полный текст  Аннотация

51. Vichinsky EP, Haberkern CM, Neumayr L, et al; The Preoperative Transfusion in Sickle Cell Disease Study Group. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med. 1995 Jul 27;333(4):206-13.Полный текст  Аннотация

52. Estcourt LJ, Fortin PM, Trivella M, et al. Preoperative blood transfusions for sickle cell disease. Cochrane Database Syst Rev. 2016 Apr 6;(4):CD003149.Полный текст  Аннотация

53. Howard J, Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet. 2013 Mar 16;381(9870):930-8. Аннотация

54. Lee MT, Piomelli S, Granger S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood. 2006 Aug 1;108(3):847-52.Полный текст  Аннотация

55. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005 Dec 29;353(26):2769-78.Полный текст  Аннотация

56. Koshy M, Burd L, Wallace D, et al. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med. 1988 Dec 1;319(22):1447-52. Аннотация

57. Boafor TK, Olayemi E, Galadanci N, et al. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG. 2016 Apr;123(5):691-8.Полный текст  Аннотация

58. Malinowski AK, Shehata N, D'Souza R, et al. Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. Blood. 2015 Nov 19;126(21):2424-35.Полный текст  Аннотация

59. Compernolle V, Chou ST, Tanael S, et al. Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline. Transfusion. 2018 Jun;58(6):1555-66. Аннотация

60. Jacobson SJ, Kopecky EA, Joshi P, et al. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet. 1997 Nov 8;350(9088):1358-61. Аннотация

61. Dampier CD, Wager CG, Harrison R, et al; Investigators of the Sickle Cell Disease Clinical Research Network (SCDCRN). Impact of PCA strategies on pain intensity and functional assessment measures in adults with sickle cell disease during hospitalized vaso-occlusive episodes. Am J Hematol. 2012 Oct;87(10):E71-4.Полный текст  Аннотация

62. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000 Jun 22;342(25):1855-65.Полный текст  Аннотация

63. Dolatkhah R, Dastgiri S. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev. 2020 Jan 16;1:CD007843.Полный текст  Аннотация

64. Bundy DG, Richardson TE, Hall M, et al. Association of guideline-adherent antibiotic treatment with readmission of children with sickle cell disease hospitalized with acute chest syndrome. JAMA Pediatr. 2017 Nov 1;171(11):1090-9.Полный текст  Аннотация

65. Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database Syst Rev. 2016 May 19;(5):CD007001.Полный текст  Аннотация

66. Eapen M, Brazauskas R, Walters MC, et al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 2019 Nov;6(11):e585-96.Полный текст  Аннотация

67. Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017 Mar 16;129(11):1548-56.Полный текст  Аннотация

68. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009 Dec 10;361(24):2309-17.Полный текст  Аннотация

69. Bolaños-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22;120(22):4285-91.Полный текст  Аннотация

70. Shenoy S, Angelucci E, Arnold SD, et al. Current results and future research priorities in late effects after hematopoietic stem cell transplantation for children with sickle cell disease and thalassemia: a consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Apr;23(4):552-61.Полный текст  Аннотация

71. Martí-Carvajal AJ, Solà I, Agreda-Pérez LH. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database Syst Rev. 2019 Dec 5;12:CD004344.Полный текст  Аннотация

72. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008 Jan 15;148(2):94-101. Аннотация

73. Anie KA, Green J. Psychological therapies for sickle cell disease and pain. Cochrane Database Syst Rev. 2015 May 8;(5):CD001916.Полный текст  Аннотация

74. US Food and Drug Administration. FDA drug safety communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. Apr 2017 [internet publication].Полный текст

75. Medicines and Healthcare Products Regulatory Agency. Codeine: restricted use as analgesic in children and adolescents after European safety review. Jun 2013 [internet publication].Полный текст

76. European Medicines Agency. Restrictions on use of codeine for pain relief in children - CMDh endorses PRAC recommendation. Jun 2013 [internet publication].Полный текст

77. Misra H, Lickliter J, Kazo F, et al. PEGylated carboxyhemoglobin bovine (SANGUINATE): results of a phase I clinical trial. Artif Organs. 2014 Aug;38(8):702-7. Аннотация

78. Misra H, Bainbridge J, Berryman J, et al. A Phase Ib open label, randomized, safety study of SANGUINATE™ in patients with sickle cell anemia. Rev Bras Hematol Hemoter. 2017 Jan-Mar;39(1):20-7.Полный текст  Аннотация

79. McArthur JG, Svenstrup N, Chen C, et al. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica. 2019 May 30 [Epub ahead of print].Полный текст  Аннотация

80. ClinicalTrials.gov. An extension study of IMR-687 in adult patients with sickle cell anemia. Aug 2019 [internet publication].Полный текст

81. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998 Jan 1;91(1):288-94.Полный текст  Аннотация

82. Stockman JA, Nigro MA, Mishkin MM, et al. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med. 1972 Oct 26;287(17):846-9. Аннотация

83. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016 Feb 13;387(10019):661-70.Полный текст  Аннотация

84. Miller ST, Jensen D, Rao SP. Less intensive long-term transfusion therapy for sickle cell anemia and cerebrovascular accident. J Pediatr. 1992 Jan;120(1):54-7. Аннотация

85. Estcourt LJ, Fortin PM, Hopewell S, et al. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database Syst Rev. 2017 Jan 17;(1):CD003146.Полный текст  Аннотация

86. Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2011 Jan 20;117(3):772-9.Полный текст  Аннотация

87. Estcourt LJ, Fortin PM, Hopewell S, et al. Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2017 May 13;(5):CD012389.Полный текст  Аннотация

88. Fortin PM, Hopewell S, Estcourt LJ. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2018 Aug 1;(8):CD012082.Полный текст  Аннотация

89. Vichinsky EP, Neumayr LD, Gold JI, et al; Neuropsychological Dysfunction and Neuroimaging Adult Sickle Cell Anemia Study Group. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA. 2010 May 12;303(18):1823-31. Аннотация

90. Krauss JS, Freant LJ, Lee JR. Gastrointestinal pathology in sickle cell disease. Ann Clin Lab Sci. 1998 Jan-Feb;28(1):19-23. Аннотация

91. Omata M, Johnson CS, Tong M, et al. Pathological spectrum of liver diseases in sickle cell disease. Dig Dis Sci. 1986 Mar;31(3):247-56. Аннотация

92. Schubert TT. Hepatobiliary system in sickle cell disease. Gastroenterology. 1986 Jun;90(6):2013-21. Аннотация

93. Seguier-Lipszyc E, de Lagausie P, Benkerrou M, et al. Elective laparoscopic cholecystectomy. Surg Endosc. 2001 Mar;15(3):301-4. Аннотация

94. Bonatsos G, Birbas K, Toutouzas K, et al. Laparoscopic cholecystectomy in adults with sickle cell disease. Surg Endosc. 2001 Aug;15(8):816-9. Аннотация

95. Owusu-Ofori S, Remmington T. Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. Cochrane Database Syst Rev. 2017 Nov 7;(11):CD003425.Полный текст  Аннотация

96. Claster S, Vichinsky EP. Managing sickle cell disease. BMJ. 2003 Nov 15;327(7424):1151-5.Полный текст  Аннотация

97. Rodgers GP, Roy MS, Noguchi CT, et al. Is there a role for selective vasodilation in the management of sickle cell disease? Blood. 1988 Mar;71(3):597-602.Полный текст  Аннотация

98. Myint KT, Sahoo S, Thein AW, et al. Laser therapy for retinopathy in sickle cell disease. Cochrane Database Syst Rev. 2015 Oct 9;(10):CD010790.Полный текст  Аннотация

99. Morgan AG. Sickle cell leg ulcers. Int J Dermatol. 1985 Dec;24(10):643-4. Аннотация

100. Castro O, Gladwin MT. Pulmonary hypertension in sickle cell disease: mechanisms, diagnosis, and management. Hematol Oncol Clin North Am. 2005 Oct;19(5):881-96. Аннотация

101. Klings ES, Machado RF, Barst RJ, et al.; American Thoracic Society Ad Hoc Committee on Pulmonary Hypertension of Sickle Cell Disease. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014 Mar 15;189(6):727-40. Аннотация

102. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol. 2005 Aug;130(3):445-53.Полный текст  Аннотация

103. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1;334(5):296-301.Полный текст  Аннотация

104. McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med. 1999 May 4;130(9):740-3. Аннотация

105. Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 2011 Jul 28;118(4):855-64.Полный текст  Аннотация

106. Olaosebikan R, Ernest K, Bojang K, et al. A randomized trial to compare the safety, tolerability, and effectiveness of 3 antimalarial regimens for the prevention of malaria in Nigerian patients with sickle cell disease. J Infect Dis. 2015 Aug 15;212(4):617-25.Полный текст  Аннотация

107. Liem RI, Lanzkron S, D Coates T, et al. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv. 2019 Dec 10;3(23):3867-97.Полный текст  Аннотация

108. Mantadakis E, Cavender JD, Rogers ZR, et al. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):518-22. Аннотация

109. Arduini GAO, Trovó de Marqui AB. Prevalence and characteristics of priapism in sickle cell disease. Hemoglobin. 2018 Mar;42(2):73-7. Аннотация

110. Phebus CK, Gloninger MF, Maciak BJ. Growth patterns by age and sex in children with sickle cell disease. J Pediatr. 1984 Jul;105(1):28-33. Аннотация

111. Fung EB, Harmatz PR, Milet M, et al. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion. 2008 Sep;48(9):1971-80. Аннотация

112. Meerpohl JJ, Schell LK, Rücker G, et al. Deferasirox for managing transfusional iron overload in people with sickle cell disease. Cochrane Database Syst Rev. 2014 May 27;(5):CD007477.Полный текст  Аннотация

113. Sridharan K, Sivaramakrishnan G. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Expert Rev Clin Pharmacol. 2018 Jun;11(6):641-50. Аннотация

114. World Health Organization. Medical eligibility for contraceptive use. 5th ed. Geneva: World Health Organization; 2015.Полный текст

115. Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2005:58-65.Полный текст  Аннотация

116. Haddad LB, Curtis KM, Legardy-Williams JK, et al. Contraception for individuals with sickle cell disease: a systematic review of the literature. Contraception. 2012 Jun;85(6):527-37. Аннотация

Использование этого контента попадает под действие нашего заявления об отказе от ответственности